Ciprofloxacin Prevents Myelination Delay in Neonatal Rats Subjected to E. coli Sepsis

To cite this version:

HAL Id: hal-02470193
https://hal.sorbonne-universite.fr/hal-02470193
Submitted on 20 Feb 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Ciprofloxacin Prevents Myelination Delay in Neonatal Rats Subjected to E. coli Sepsis

Gauthier Loron, MD, 1 Paul Olivier, PhD, 1 Hélène See, MD, 1,2 Nolwenn Le Saché, MD, 1,2 Leslie Angulo, 1,2 Valérie Biran, MD, PhD, 1,7,8 Nadège Brunelle, PhD, 3 Bernadette Besson-Lescure, PhD, 3 Marie-Dominique Kitzis, PhD, 4 Julien Pansiot, MS, 1 Edouard Bingen, MD, 2,5 Pierre Gressens, MD, PhD, 1,6,7 Stéphane Bonacorsi, MD, PhD, 2,5 and Olivier Baud, MD, PhD 1,7,8

Objective: Perinatal infections and the systemic inflammatory response to them are critical contributors to white matter disease (WMD) in the developing brain despite the use of highly active antibiotics. Fluoroquinolones including ciprofloxacin (CIP) have intrinsic anti-inflammatory effects. We hypothesized that CIP, in addition to its antibacterial activity, could exert a neuroprotective effect by modulating white matter inflammation in response to sepsis.

Methods: We adapted an Escherichia coli sepsis model to 5-day-old rat pups (P5), to induce white matter inflammation without bacterial meningitis. We then compared the ability of CIP to modulate inflammatory-induced brain damage compared with cefotaxime (CTX) (treatment of reference).

Results: Compared with CTX, CIP was associated with reduced microglial activation and inducible nitric oxide synthase (iNOS) expression in the developing white matter in rat pups subjected to E. coli sepsis. In addition to reducing microglial activation, CIP was able to prevent myelination delay induced by E. coli sepsis and to promote oligodendroglial survival and maturation. We found that E. coli sepsis altered the transcription of the guidance molecules semaphorin 3A and 3F; CIP treatment was capable of reducing semaphorin 3A and 3F transcription levels to those seen in uninfected controls. Finally, in a noninfectious white matter inflammation model, CIP was associated with significantly reduced microglial activation and prevented WMD when compared to CTX.

Interpretation: These data strongly suggest that CIP exerts a beneficial effect in a model of E. coli sepsis-induced WMD in rat pups that is independent of its antibacterial activity but likely related to iNOS expression modulation.

ANN NEUROL 2011;69:341–351

White matter disease (WMD) is the major pathology underlying the cerebral palsy and cognitive impairment observed in very preterm neonates who survive the intensive care unit. In the most recent epidemiological reports, the incidence of WMD in infants with a gestational age of less than 32 weeks is as high as 20%. 1,2 Several perinatal factors, including maternal or neonatal infection, hypoxia-ischemia, endocrine imbalances, and genetic factors have been implicated in the pathophysiology of brain lesions associated with WMD. 3

Perinatal infections resulting in an excess of cytokines and other proinflammatory agents are one of the most striking contributors to WMD in the developing brain. 4 Infants with sepsis have recently been shown to have a very high incidence (80%) of white matter abnormalities. 5,6 Escherichia coli is one of the main pathogens...
causing early-onset infections in preterm neonates, accounting for up to 40% of the cases of bacteremia among very low birth weight preterm infants (<1,500 g). During the last decade, the incidence of early-onset *E. coli* infections has increased to 0.5% to 1% in this high-risk population.²,⁸

Fluoroquinolones are antibiotics with bactericidal activity that inhibit DNA gyrase, an enzyme essential for bacterial DNA synthesis. These antibiotics, although not approved for use in neonates, have been previously used with success in multidrug-resistant or complicated Gram-negative infections, with no major adverse effects.⁹,¹⁰ Indeed, this class of drugs has several advantages compared to beta-lactam antibiotics, the antibacterial agents of reference in neonatal infections, such as bactericidal activity on stationary-phase bacteria and good tissue diffusion, especially in the central nervous system (CNS).¹¹ However, ciprofloxacin (CIP) has only a moderate efficacy against Gram-positive bacteria, especially Group B Streptococcus and cannot replace cefotaxime (CTX) in a context of empiric antibiotic therapy.

In addition to their antibacterial activity, fluoroquinolones possess intrinsic anti-inflammatory effects, decreasing the expression of pro-inflammatory cytokines and inducible nitric oxide synthase (iNOS).¹²⁻¹⁴ In very preterm infants at high risk of developing brain lesions, the use of such antibiotics, combining antibacterial activity and anti-inflammatory properties, would constitute an original approach, since perinatal inflammation is considered one of the strongest predictors of WMD.

Here, we hypothesized that the intrinsic anti-inflammatory properties of the fluoroquinolone CIP may have neuroprotective effects in the developing brain subjected to *E. coli* sepsis. Using an animal model characterized by perinatal *E. coli* sepsis without meningitis, we demonstrate that systemic sepsis is associated with inflammation and transient myelination defects in the immature white matter. Compared to CTX as the treatment of reference, CIP is able to prevent WMD through the modulation of white matter inflammation in response to *E. coli* sepsis.

**Subjects and Methods**

**Bacterial Strains**

*E. coli* strain C5 was kindly provided by Robert Bortolussi (Dalhousie University, Halifax, Canada), and is representative of the worldwide highly virulent clonal group O18:K1:H7 that causes neonatal bacteremia and meningitis.¹⁵ C5 is sensitive to all antibiotics, and minimal inhibitory concentrations for CTX and CIP were 0.06 µg/ml and 0.015 µg/ml, respectively.

**Antibiotics and Pharmacokinetics**

We used CTX (Sanofi-Aventis, France) diluted in physiological saline, and a commercial intravenous solution of CIP (2mg/ml; Bayer, France). The dose of CTX administered (50 mg/kg/injection) was identical to that previously reported in an experimental model of neonatal infection.¹⁶ For CIP, doses were calibrated to achieve a serum concentration within the human therapeutic range 1 to 2 hours after injection. Pharmacokinetic assays were performed in pups as follows. Blood samples were obtained immediately after sacrifice from 3 to 6 pups per group, at selected time points (30, 60, 90, and 120 minutes after subcutaneous antibiotic administration). Sera were conserved at −20°C. Antibiotic concentrations were determined by the agar disk diffusion test (microbiological assay), as described by Klassen and Edberg.¹⁷

As expected, the serum concentration of CTX 1 hour after injection in rat pups, 99.4 ± 15.2 µg/ml, was found to be in the therapeutic range of concentrations usually observed in humans. Among the several doses of CIP tested, a dose of 7.5 mg/kg/injection was chosen since the peak concentration at 1 hour, 5.5 ± 0.7 µg/ml, was considered to be close to that observed in humans.

**Animal Models**

All experimental and animal housing procedures complied with INSERM guidelines and with the Policies on the Use of Animals and Humans in Neuroscience Research.

**NEONATAL E. COLI SEPSIS.** An *E. coli* sepsis model was adapted to rat pups from a previously reported study, in order to induce white matter inflammation and damage without bacterial meningitis.¹⁸ Pathogen-free 4-day-old Sprague-Dawley rat pups were obtained from Charles River Laboratories (France) along with their mothers. At 5 days of age (P5), all pups were inoculated intraperitoneally with ~5,000 colony-forming units (CFU) of the C5 strain in physiological saline. Antibiotics were given subcutaneously at 7.5 hours and 24 hours postinfection. These 2 injections were found to be sufficient to sterilize blood culture in infected animals. At several experimental time points (before treatment, 1 hour, 3 hours, and 24 hours after first injection of antibiotics), 5 µl of blood was obtained by tail incision and quantitative cultures were performed as previously described.¹⁵ Cerebrospinal fluid (CSF) samples were obtained as previously described from 20 animals sacrificed 7.5 hours postinfection in order to control the absence of bacterial meningitis.¹⁸ The detection limit of bacteria in blood was 4 × 10⁴ CFU/ml. Neonates with negative blood cultures at 7.5 hours postinfection were considered nonbacteremic and were removed from the analysis. Bacteremic animals were sacrificed at P7, P10, and P21 for extensive brain analyses.

**GESTATIONAL HYPOXIA.** Pregnant Sprague-Dawley rats (Charles River Laboratories, France) were placed in normoxic or hypoxic (10% O₂-90% N₂) gas chambers (Biospherix, Redfield, NY) from embryonic day 5–19 as previously described.¹⁹ After delivery, normoxic (control) and hypoxic pups given either CTX or CIP treatment on P0 and P1 were studied on P3 and P10 to assess microglial activation and myelination, respectively.
**Immunohistochemistry**

In each experimental group, we studied at least 6 pups in 3 separate experiments. Immunolabeling with the primary antibody listed in Supporting Table S1 was visualized using the streptavidin-biotin-peroxidase method, as previously described. The Olig2 marker was used to visualize all oligodendrocytes, and adenomatous polyposis coli (APC) and myelin basic protein (MBP) were used to detect postmitotic oligodendrocytes and myelinated fibers, respectively. As previously described, most of the Olig2 nuclei did not colocalize with glial fibrillary acidic protein–positive cells. Double-labeling was performed with secondary antibodies coupled to the green fluorescent marker Fluoroprobes S488 (Interchim, Montluçon, France) or the red fluorescent marker cyanine 3 (Jackson Immunoresearch Laboratories, West Grove, PA).

**Quantitative Measurements**

All quantitative measurements were carried out by observers who were blind to the experimental group of the animal under study.

**IMMUNOREACTIVE CELLS.** Immunoreactive cells were counted in the white matter underlying the cortex (+2.16 to −0.36 mm from the bregma). Immunoreactive cells were counted within a 0.065 mm² grid (at 400× magnification) in at least 4 sections per animal and at least 6 animals per group at the 2 sacrifice times (P7 and P10).

**OPTICAL DENSITY OF MBP-POSITIVE FIBERS** The optical density of MBP-immunoreactive fibers was measured in the cingulum in coronal sections (+2.16 to −0.36 mm from the bregma) as previously reported. At least 4 sections each from 6–10 animals per group were examined on P10. The optical density was measured at 100× magnification using a computerized image analysis system (ImageJ, NIH; http://rsb.info.nih.gov/ij) that read optical density as gray levels. Nonspecific background densities were measured at each brain level in a region devoid of MBP immunostaining, and subtracted from values for the cingulum.

**Quantitative Real-Time Polymerase Chain Reaction**

DNA-free total RNA from normoxic and hypoxic brain cortices including the white matter was obtained using a protocol adapted from Chomczynski and Sacchi. The primers for real-time polymerase chain reaction (RT-PCR) were designed using M-fold and Oligo6 software, based on published complementary DNA (cDNA) sequences for genes of interest (see Supporting Table S2). The nature of the amplified DNA was confirmed by sequencing. To standardize gene expression across samples, we used hypoxanthine-guanine phosphoribosyltransferase (HPRT), a housekeeping gene remaining highly stable among the different samples and treatment conditions. For reverse transcription, we used 600ng of total RNA and the Iscript cDNA synthesis kit (Bio-Rad, Marne la Coquette, France). RT-PCR was set up using SYBR green–containing supermix (Bio-Rad) for 50 cycles with a 3-step program (25-second denaturation at 96°C, 30-second annealing at 60°C, and 30-second extension at 72°C). Amplification specificity was assessed by melting curve analyses. Each experiment was run twice with at least 6 animals per group, and in both cases measurements were carried out in triplicate.

**Luminex Analysis of Cytokine Concentrations**

Serum concentrations of 8 cytokines were measured using the Luminex xMAP technique (multianalytic profiling) according to the manufacturer’s guidelines (Bio-Rad). The detection and quantification of cytokine levels was performed using a Bio-Plex 200 system (Bio-Rad). Analysis of data was performed using Bio-Plex Manager 5.0 software (Bio-Rad).

**Statistical Analysis**

All data were reported as means ± standard error (SEM). Analysis of variance was performed with age and group (uninfected, CTX-treated, or CIP-treated animals) as factors, and the Newman-Keuls post-hoc nonparametric test was used. Statistical tests were run on GraphPad Software, San Diego, CA.

**Results**

**Establishment of an E. coli Sepsis Model and Curative Antibiotic Treatments in Neonatal Rats**

In our animal model characterized by perinatal E. coli sepsis, bacteremia was detected in 70 of 76 (92%) P5 animals 7.5 hours after E. coli inoculation, and ranged from 4.8 × 10⁵ to 3.2 × 10⁶ CFU/ml. By sampling CSF from 20 infected pups, we confirmed that none of the animals with bacteremia had meningitis at this early time point. Antibiotic treatment was associated with a high rate of cure. We performed quantitative cultures of blood samples at 1 and 3 hours after the first dose of antibiotics. No difference in bacterial clearance has been observed between the 2 antibiotics (Supporting Fig S1). Only 1 in 37 and 5 in 39 neonatal rats died 24 hours after treatment with CIP and CTX, respectively. In the survivors, bacteremia was no longer detectable after 24 hours of treatment. In contrast, 100% of rat pups with bacteremia died within 24 hours in the absence of antibiotic treatment.

**E. coli Sepsis Induces an Inflammatory Response in the Developing White Matter**

The consequences of E. coli sepsis in the developing CNS were first investigated by assessing microglial activation throughout the developing white matter. We compared at P7 and P10 sham-infected pups and infected pups treated either with the reference antibiotic CTX or with CIP. Neither CTX nor CIP induced altered microglial activation, morphology, or density in sham-infected pups compared to untreated sham-infected pups. E. coli
sepsis was associated with a dramatic increase in the density of activated microglia in the white matter of infected rat pups (Fig 1A, B). However, activated microglial density was found to be significantly lower in CIP-treated animals than in CTX-treated pups \( (p < 0.05) \). This observation did not appear to be related to a difference in bacteremia between the 2 groups at any time points investigated (Supporting Fig S1). Indeed, before antibioticit treatment was initiated, bacterial concentrations were similar in rat pups that received CTX and in those that received CIP \( (4.65 \pm 0.45 \log \text{CFU/ml} vs 4.84 \pm 0.79 \log \text{CFU/ml}; p > 0.05) \). No difference in bacterial clearance has been observed between the 2 antibiotics 1 hour and 3 hours after the first dose of antibiotics. Bacteremia was no longer detectable after 24 hours of treatment.

**Cytokine Production in Response to E. coli Sepsis in Blood and CNS Compartments**

Because microglial activation in the CNS could be related to our model of systemic inflammation, we next explored the impact of systemic E. coli sepsis on cytokine production in rat pups (Fig 2). Before antibiotic treatment (7.5 hours after inoculation), the concentrations of several proinflammatory cytokines (including interleukin [IL]-1\( \beta \), IL-6, and tumor necrosis factor [TNF]-\( \alpha \) were found to be increased in infected pups when compared to sham-infected controls (see Fig 2A). IL-10 and interferon-\( \gamma \) was also increased, whereas the serum concentration of IL-4 was decreased in response to E. coli sepsis (data not shown). Twenty-four hours after antibiotic initiation, both CTX and CIP were associated with a similar decrease in proinflammatory cytokine concentrations in infected rat pups. Similarly, proinflammatory cytokine gene expression was found to be increased in brain tissue in response to E. coli sepsis. Again, antibiotics were able to reverse this overexpression but no difference was detectable between CTX and CIP (see Fig 2B).

Because reduction in activated microglia density in the CIP group was not associated with detectable cytokine production modulation, we next investigated inducible NO synthase, 1 of the major components of microglial activation. Using immunocytochemistry, we found that E. coli sepsis significantly induced iNOS expression in P10 rat pups. Compared to CTX treatment, CIP significantly reduced this induction in infected animals (Fig 3A–D). As expected, all iNOS-positive cells colocalized with microglial cells labeled using tomato lectin (see Fig 3E).

**E. coli Sepsis Is Associated with Defective Myelination**

We next investigated the impact of neonatal sepsis-induced microglial activation on myelination of the developing white matter. Neither CTX nor CIP had any effect on myelination in the developing white matter of sham-infected P10 and P21 rat pups. Infected animals treated with the reference antibiotic CTX demonstrated altered myelin content in the lateral corpus callosum (Fig 4A). The density of MBP in these animals was found to be 40% lower than in uninfected controls on P10. However, this phenomenon was transient, as no further differences were observed on P21. This myelination delay was independent of the brain area considered, and was observed in both the cingulate white matter and the genu of the corpus callosum. Compared to CTX treatment, CIP significantly reduced the occurrence of a myelination delay in infected animals. CIP-treated animals exhibited a density of MBP similar to that of uninfected pups (see Fig 4B). These findings were all independent of gender.

**CIP Enhances Oligodendroglial Maturation and Survival in Neonatal Rats Subjected to E. coli Sepsis**

We next asked the question of whether the deficient myelination observed in infected pups could be related to a modulation of oligodendroglial cell death or maturation. We compared the density of the total oligodendroglial...
population (olig2+ cells) within the white matter of control and infected P10 rat pups treated with either CTX or CIP. E. coli sepsis was associated with a marked decrease in the density of olig2+ oligodendrocytes in CTX-treated animals in the lateral corpus callosum (Fig 5A). In contrast, CIP was able to significantly prevent this decrease (see Fig 5A). Consistent with these observations, the increase in oligodendroglial cell death (the density of oligodendroglial cells that stained for oligog2/terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end labeling [TUNEL] double-positive cells) observed in CTX-treated rat pups when compared to controls was not seen in CIP-treated animals (see Fig 5B).

The density of mature oligodendrocytes (APC+ cells) was found to be lower in CTX-treated but not in CIP-treated rat pups compared to uninfected animals on P10 (see Fig 5C). Concordantly, CTX-treated animals exhibited a significantly higher density of olig2/Ki67 double-positive cells than either uninfected or CIP-treated animals (see Fig 5D). Finally, the density of mature oligodendrocytes (APC+ cells) among olig2+ oligodendrocytes was found to be higher in CIP-treated compared to CTX-treated rat pups on P10 (see Fig 5E). These results suggest that CIP treatment reduced the oligodendroglial cell death observed in infected pups treated with CTX, and led to the conservation of oligodendroglial maturation in the injured white matter.

We next explored the impact of antibiotic treatment on the relative expression of semaphorin 3A and 3F, which are involved in the myelination of axons in the CNS. Semaphorin 3A and 3F are known to act as axonal guidance cues and chemotactic factors for oligodendrogial cells in the developing CNS.23,24 Semaphorin 3A is associated with a repulsive signal and semaphorin 3F with an attractive signal toward migrating oligodendrocyte precursor cells. In our study, E. coli sepsis was associated with a remarkable upregulation of semaphorin 3A and downregulation of semaphorin 3F expression (Fig 6A,B). Interestingly, CIP and CTX treatments resulted in the differential regulation of the transcription of these 2 genes: CTX only partially attenuated the effects of E. coli sepsis, whereas CIP completely reversed them. These data suggest that CIP could have a specific impact on the expression of the guidance molecules semaphorin 3A and 3F, and may thus determine the ability of injured white matter to remyelinate.

CIP Prevents Myelination Deficits in a Noninfectious Rat Model of WMD

We hypothesized that the CIP-related neuroprotection observed in our E. coli sepsis model could be due to its intrinsic anti-inflammatory properties and not to its antibacterial activity. To test this hypothesis, we used both CIP and CTX (2 subcutaneous injections on P0–P1) in another
In this study, we developed a rat model of neonatal *E. coli* sepsis without meningitis that induces marked inflammation in the developing white matter. This model is relevant in light of recent clinical studies demonstrating that postnatal sepsis accounts for a large proportion of WMD in very preterm infants.\(^5,25\) Our animal model, developed at P5, closely mimics the pathological features observed in infected preterm infants, including white matter inflammation and myelination delay. These alterations occur at a developmental stage of the rat brain that corresponds to the human brain at 28–32 weeks of gestation,\(^26\) recognized as the period during which the developing brain is most vulnerable to either hypoxic or inflammatory insults.\(^27\)

Lipopolysaccharide (LPS) has been previously used to mimic perinatal bacterial infection and to study the consequences of inflammation in the developing brain.\(^3\) However, although LPS is a major bacterial determinant in the activation of the innate immune system, models using this component may not reflect the complexity of Gram-negative sepsis and its subsequent treatment with antibiotics. *E. coli* per se has been used to induce brain damage in both antenatal rabbit and rodent models.\(^28–30\) To our knowledge, our model is the first to explore the effects of postnatal sepsis and antibiotic treatment on the developing brain.

Several lines of evidence support the relationship between *E. coli* sepsis and WMD in our model. First, postnatal *E. coli* sepsis induces hypomyelination of the
Several experimental studies have demonstrated a similar effect of LPS given antenatally to rabbits and sheep. Second, we have also observed that *E. coli* sepsis induces an increase in oligodendroglial cell death in the developing white matter. This finding is consistent with recent data demonstrating that immature oligodendrocytes are highly vulnerable to both inflammation and oxidative stress. Finally, we found here that *E. coli* sepsis induced increased serum concentrations of TNF-α and IFN-γ that have been shown to block the differentiation of oligodendrocyte precursors in vitro.

Interestingly, our model has unveiled a new pathophysiological consequence of *E. coli* sepsis, with the specific regulation of semaphorin 3A and 3F. A recent report has demonstrated that semaphorin 3A (repulsive) and 3F (attractive) are involved in the control of oligodendrocyte precursor cell migration in multiple sclerosis, and hence may determine the ability of plaques to remyelinate. In demyelinating diseases, remyelination could fail either because oligodendrogial progenitors fail to repopulate areas of demyelination, or because they are unable to generate remyelinating oligodendrocytes in the presence of persistent inflammation.

Taken together, our results suggest that the *E. coli* sepsis model is relevant to WMD, being able to account for myelination delay through several pathways including increased oligodendroglial cell death, impairment of oligodendroglial maturation, imbalance in axonal guidance, and reduced attraction of axons to myelin sheets, and finally, impaired regeneration of injured white matter areas. We therefore used this model to assess the consequences of treatment with 2 antibiotics in WMD.

Our comparative study of CTX and CIP strongly suggests that CIP exerts a neuroprotective effect in our model of *E. coli* sepsis-induced WMD, probably through the modulation of white matter inflammation. Several in vitro studies but only a few reports using in vivo models with living microorganisms showed that fluoroquinolones, including CIP, inhibit the synthesis of proinflammatory cytokines such as TNF-α, IL-1β, and IL-6. In most of the in vitro previous studies, concentrations of fluoroquinolones were much higher than those observed in clinical setting. Here, we failed to demonstrate that CIP induced inhibition in the synthesis of proinflammatory cytokines in vivo. The lower (and clinically relevant) antibiotic concentrations used in our model may explain this discrepancy at
FIGURE 5: CIP enhances oligodendroglial maturation and survival in neonatal rats subjected to E. coli sepsis. (A) Quantitative analysis of Olig2-immunoreactive cells in the cingulate white matter at P10. CIP treatment reverses the loss of mature oligodendrocytes observed in infected CTX-treated pups. **p < 0.01 and ***p < 0.001, using 1-way ANOVA with the Newman-Keuls correction, n = 6 for each experimental group. (B) Quantification of TUNEL+ oligodendrocytes (Olig2+) in the hemispheric white matter. CIP treatment prevents the increase in oligodendrocyte cell death observed in infected CTX-treated pups. **p < 0.01 using 1-way ANOVA with the Newman-Keuls correction, n = 6 for each experimental group. (C) Quantitative analysis of APC-immunoreactive cells in the cingulate white matter at P10. CIP treatment reverses the loss of mature oligodendrocytes observed in infected CTX-treated pups. **p < 0.01 and ***p < 0.001, using 1-way ANOVA with the Newman-Keuls correction, n = 10–13 for each experimental group. (D) Quantitative analysis of the Ki67/Olig2-positive cells in the cingulate white matter of controls (Ct, n = 8) and infected CTX-treated (n = 12) and CIP-treated (n = 10) animals. *p < 0.05 using 1-way ANOVA with the Newman-Keuls correction. (E) APC/Olig2-immunoreactivity in the cingulate white matter of P10 rat pups, demonstrating the increase in the density of double-labeled oligodendrocytes (mature; arrows) after CIP treatment. Bar = 100 μm. ANOVA = analysis of variance.
least in part. Conversely, we found that CIP was able to significantly reduce the iNOS overexpression induced by E. coli sepsis in microglial cells. Intense iNOS expression occurred in activated microglia during the acute stage of WMD in humans.39 Therefore, inhibition of iNOS-induced nitrosative stress by CIP could have beneficial effect in the injured developing white matter.

In the literature, several initial targets have been suggested to explain the anti-inflammatory property of the fluoroquinolones: (1) the inhibitory effect of phosphodiesterase and the subsequent intracellular accumulation of cyclic adenosine monophosphate and activation of protein kinase C; (2) the increase in the gene transcription of nuclear factor of activated T cells (NFAT-1), activator protein-1 (AP-1), and nuclear factor IL-2A40,41; (3) the inhibition of nuclear factor kappa B activation42; and (4) the decrease in the expression of the LPS...
receptor complex. These particular properties seem to be shared only by fluoroquinolones harboring a cyclopropyl group at the N1 position or a piperazinyl group at the C7 position. Interestingly, CIP is particular among fluoroquinolones, as both residues are present on this molecule. To date, the clinical relevance of inflammatory modulation by the fluoroquinolones remains to be determined. Indeed, in human studies, the clinical benefits of such an effect are still uncertain. Gogos and colleagues have shown that CIP attenuates the proinflammatory response as compared to cephalosporins, in patients with Gram-negative sepsis. However, this difference has no impact on the outcome.

In premature neonates, E. coli is the major cause of early onset sepsis. The molecule of choice to treat such infections is a third-generation cephalosporin such as CTX. Although this antibiotic is highly effective against E. coli, beta-lactam cell wall activity may cause the release of cell wall components such as LPS, which can lead to an excessive inflammatory response. Fluoroquinolones that do not target bacterial membranes might induce a lower release of LPS and subsequently, the lower expression of proinflammatory cytokines than cephalosporins. However, the effect of CIP on endotoxin release remains controversial. In our model, we failed to demonstrate any difference in systemic cytokine patterns induced by the 2 antibiotics. We could thus speculate that the neuroprotection afforded by CIP is likely due to a direct effect on the developing CNS.

It remains to be determined if CIP exerts its neuroprotective effect by counteracting the effects of systemic cytokines on the CNS, or by preventing the deleterious effects of hypoxia, consequently to sepsis.

In conclusion, this study provides strong evidence for a novel neuroprotective property of ciprofloxacin in neonatal rat models of inflammation-induced brain lesions possibly related to modulation of iNOS expression in the developing white matter. The impact of CIP needs to be further explored in other perinatal inflammatory conditions such as chorioamnionitis and necrotizing enterocolitis. Delineating the molecular determinants of the neuroprotective effects of CIP could lead to the design of potential new candidates for the prevention of noninfectious WMD or the enhancement of myelin repair.

Authorship
S.B. and O.B. contributed equally to this work.

Potential Conflicts of Interest
Nothing to report.

References


